EVER-PHARMA-GMBH
After successfully launching the D-mine ® Pump, an infusion device designed to provide precise continuous subcutaneous drug delivery for Parkinson´s patients, EVER Pharma developed an App to support the training needs of Healthcare Professionals and caregivers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005103/en/
EVER Pharma, a specialist in neurological diseases, offers a complete therapy package for Parkinson’s disease with D-mine ® Pump , D-mine ® Pen and Dacepton® (Dopaceptin® , Apomorphine hydrochloride) and with its new D-mine ® Pump TRAINING APP a simulation tool to support the training and the programing of the D-mine ® Pump.
The App can be easily downloaded and installed onto Android or iOS devices by Healthcare Professionals or caregivers who are working with the D-mine ® Pump and managing the therapy of Parkinson´s patients with infusion therapy.
“With the development of the TRAINING APP for the D-mine ® Pump in Parkinson's therapy, we now have an empowering and interactive tool to support the training of the Healthcare Professionals and caregivers on how to use and program the infusion pump device. The App is an intuitive, easy-to-use simulator and enables training any time everywhere”, explains Georges Kahwati, General Manager at EVER Pharma GmbH.
For more information please visit www.d-minecare.com .
About EVER Pharma GmbH
EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production and commercialization of products in the areas of neurology, critical care, anesthesia and oncology.
From its global headquarters in Austria, Ever Pharma provides innovative therapies and value-added formulations aimed at enhancing patient and healthcare professional’s lives through improved safety and convenience.
The products are developed and manufactured at EU GMP certified facilities in Austria and Germany. The technical operations are highly specialized in the production of complex injectables including high potency substances, crystal suspensions, oily solutions and controlled substances in vials, pre-filled syringes, cartridges, ampoules and implants. EVER markets its products in more than 80 countries around the world through 30 international affiliated companies and strategic partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005103/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"23.10.2025 09:00:00 CEST | Press release
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity's gene therapy, RDP-101, for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. If approved by the U.S. Food and Drug Administration, RDP-101 would be the first gene therapy available for commercial use to reverse ADA-SCID in patients within the United States. ADA-SCID is a rare, life-threatening inherited condition that severely compromises the immune system, leaving infants vulnerable to frequent and severe infections. For every million babies born worldwide, it is estimated that between one and five will have this condition. The ADA-SCID disorder caused by an Adenosine Deaminase deficiency is f
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 08:01:00 CEST | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022347041/en/ TOURISE and Globant Unveil New White Paper on Agentic AI in Tourism In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP, and is projected to reach 16.5 trillion dollars by 2035. AI
Bureau Veritas:Robust and Consistent Revenue Performance Delivered in Q3 2025; FY 2025 Outlook Reaffirmed23.10.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022995674/en/ Hinda Gharbi, CEO Bureau Veritas Q3 2025 Key figures1 › Revenue of EUR 1,583.7 million, up 2.3% year-on-year and up 6.3% organically › A very strong organic growth from Marine & Offshore at 16.2%; solid recovery of Buildings & Infrastructure at 7.1% organically; strong organic growth maintained for both Industry and Certification, at 6.9% and 5.9% respectively, against challenging comparables; moderate organic growth for Consumer Products Services at 3.5% and Agri-Food & Commodities at 2.5% › Positive scope effect of 0.8%, from the accelerated pace of bolt-on acquisitions (+3.1% contribution) realized, net of disposals (-2.3% contribution) › Negative currency impact of 4.8%, resulting from the euro’s appreciation against most currencies Q3 2025 Highlights › Continued progress in implementing the LEAP I 28 strategy, delivering results
Bureau Veritas Accelerating Its LEAP | 28 Strategy With Two Signed Agreements for Acquisitions in Buildings & Infrastructure and Renewables23.10.2025 07:20:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification (TIC) services, announces that it has signed agreements to acquire two companies in Europe, reinforcing its leading position and expanding into high-potential markets: Sólida in the renewables sector, and London Building Control in the Buildings & Infrastructure market. These agreements underscore Bureau Veritas’ commitment to growth within its LEAP I 28 strategy, increasing capability, reach, and technical expertise across growth markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022071543/en/ Hinda Gharbi, CEO Bureau Veritas Sólida is a top-tier provider of Owner’s Engineering, Technical Advisory, and Project Management services for renewable energy projects and electrical infrastructure. It acts as a trusted technical partner for leading developers, utilities, EPC contractors, investment funds and financial institutions. The Company has demo
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance23.10.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio. Record net sales of 3.737 billion USD for the first nine months of the year, representing net sales growth of 15.0% at constant currency1, despite challenging market dynamics, driven primarily by volume growth complemented by favorable mix Widespread growth with acceleration across all geographies and product categories, including Injectable Aesthetics (+10.5%) with some phasing benefits in Neuromodulators, Dermatological Skincare (+8.2%), and Therapeutic Dermatology (+40.4%), all year-on-year for the first nine months of 2025 at constant currency Advancing future growth drivers across the portfolio, led by the strong commercial momentum of Nemluvio® as well as the ramp-up of multiple launches in fl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom